tbuckley/cabot-search huggingface dataset:
Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas
Authors: P. Casali, U. Pastorino, P. Zucchinelli, L. Devizzi, A. Azzarelli, V. Quagliuolo, P. Bignami, A. Santoro, G. Bonadonna
Journal: Annals of Oncology (1992)
Abstract 826: Yes-associated protein increases hepatocellular carcinoma chemosensitivity by modulating p53
Authors: Nan Bai, Chunyan Zhang, Antao Chang, Zhuhong Zhang, Jing Yin, Rong Xiang, Chenghu Liu
Journal: Cancer Research (2012)

Abstract The function of the yes-associated protein (YAP) transcription co-activator remains an enigma since reports indicate that YAP either acts as an oncogene or enhances apoptosis. In this study, we found that YAP expression occurs in 51% of human hepatocellular carcinoma (HCC) biopsies while phosphorylated YAP (pYAP) expression occurs in 33% of Grade II and III HCCs. In addition, we found that YAP and p53 expression/ nuclear translocation increase in chemo-treated HepG2 cells. In chemo-treated HepG2 cells transfected with WT-YAP or blank (control), the chemosensitivity of the HepG2 + WT-YAP cells increases compared to HepG2+blank cells. In chemo-treated HepG2 cells transfected with Flag-S94A (TEAD binding domain mutant), Flag-W1W2 (WW domain mutant), or blank (control), the chemosensitivity and p53 expression/ nuclear translocation of the HepG2+Flag-S94A cells and HepG2+Flag-W1W2 cells decrease compared to HepG2+blank cells. In chemo-treated HepG2 cells transfected with Flag-5SA-S94A or Flag-5SA-W1W2, the chemosensitivity and p53 expression/ nuclear translocation of the HepG2+Flag-5SA-S94A cells and HepG2+Flag-5SA-W1W2 cells increase again compared to HepG2+Flag-S94A cells or HepG2+Flag-W1W2 cells respectively. These results indicate that YAP promotes chemosensitivity by modulating p53 during chemo-treatment, and YAP-modulated p53 activity requires the TEAD binding domain and the WW domain. In summary, our data indicate that YAP functions as a tumor-suppressor that enhances apoptosis by modulating p53 activity during chemo-treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 826. doi:1538-7445.AM2012-826
Abstract 4420: Analysis of functional role of interleukin-6 secreted by tumor-associated macrophages in ovarian cancer ascites
Authors: Aki Isobe, Kenjiro Sawada, Chifumi Ooyagi, Seiji Mabuchi, Atsuko Wakabayashi, Ken-Ichirou Morishige, Tadashi Kimura
Journal: Cancer Research (2011)

Abstract Tumor-associated macrophages (TAMs) are known to contribute to tumor growth, invasion, and metastasis by producing various mediators. However, few studies have clarified the role of TAMs in human ovarian cancer patients. The aim of the present study was therefore to analyze the effect of TAM on ovarian cancer growth, invasion, and metastasis. Ascites were collected aseptically, and CD11b positive cells (TAMs) were purified by positive selection using magnetic-activate cell sorting (MACS) technology. Co-culture of ovarian cancer cell line, SKOV3ip1 cells, with TAMs significantly enhanced the invasive activity of cancer cells in Matrigel Boyden chamber assay. This enhancement was partially blolcked by the treatment of anti-interleukin (IL)-6 receptor antibody (Tocilizumab). Since SKOV3ip1 cells did not express IL-6 in mRNA and protein level, IL-6 secreted by TAMs were considered to play a key role in ovarian cancer invasion. In vivo ovarian cancer xenografts, i.p. treatment of Tocilizumab significantly reduced peritoneal dissemination and ascites formation. Those results suggested targeting IL-6 produced by TAMs could be a promising therapy for a subset of ovarian cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4420. doi:10.1158/1538-7445.AM2011-4420
FRI0098 Screening for Cancer in Rheumatoid Arthritis: Results from the Comedra Study
Authors: T. Marhadour, B. Le Mat, D. Cornec, S. Jousse-Joulin, V. Devauchelle-Pensec, M. Dougados, M. Soubrier, A. Saraux
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> The aim of this study was to determine if recommendations for cancer screening were well applied in rheumatoid arthritis (RA) patients. Frequency of each cancer and risk factors were also assessed. <h3>Methods</h3> 970 patients with RA, according to ACR criteria, were included in the french COMEDRA study. A standardized questionnaire on comorbidities, including cancer, was fulfilled by a nurse or a clinical research assistant. Data were collected to assess cancer monitoring according to the french recommendation for breast (mammography each 2 years between 50 and 74 years old), cervical (smear each year after 25 years old, and after 2 normal spears each 3 years), prostate (digital rectal exam and Prostatic Specific Antigen (PSA) dosage after 50 years old, and then PSA dosage each 3 years if PSA level is &lt;1 ng/mL or each year if PSA level is between 1 and 4 ng/mL), and colorectal cancer (Hemoccult® test each 2 years between 50 and 74 years old, and colonoscopy if fecal occult blood test is positive). Prostatic Specific Antigen (PSA) was sampled in men patients before the beginning of the study. <h3>Results</h3> Data for 922/970 patients were analysable. There were 731 women and 191 men. 272/687 (39.6%) women who must have a screening (between 25 and 74 years) and 272/731 (37.2%) of the whole female population had adequate screening for breast, cervical and colorectal cancer (77.3% for 25-50 years, 29.6% for 50-65 years and 16% for 65-74 years). 22/147 (14.9%) men who must have a screening (50 to 74 years) and 54/191 (28.3%) of the whole male population had adequate screening for prostate and colon cancer. 58/922 (7.9%) of women and 12/191 (6.3%) of men had a history of cancer. Rate of cancer was: 27/731 (3.7%) for breast cancer; 10/731 (1.4%) for cervical cancer; 3/191 (1.6%) for prostate cancer; 6/922 (0.6%) for colorectal cancer; 9/922 (1%) for melanoma; 2/922 (0.2%) for lung cancer; 3/922 (0.3%) for lymphoma. 177/922 (19.2%) patients had more than 20 pack years smoking. 45/922 (4.5%) patients had an alcohol consumption above 2 glasses/day. <h3>Conclusions</h3> Despite the possibility to have a monitoring detection of cancer free of charge in France, less than 40% of women and less than 30% of men had adequate cancer screening monitoring in this study. The most common past cancer were breast cancer for women and prostate for men. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4146
Abstract 5085: Radiosensitization of castration-resistant prostate cancer via modulating autophagic cell death
Authors: Yang Qu, Jiqin Lian, Xiaoqing Wu, Wenhua Tang, Fengtian He, Min Ji, Liang Xu
Journal: Cancer Research (2011)

Abstract Radioresistance markedly impair the efficacy of cancer therapy. Anti-apoptotic Bcl-2 family proteins such as Bcl-xL, Bcl-2 and Mcl-1 are overexpressed in castration-resistant prostate cancer (CRPC) and contribute to prostate tumor initiation, progression and resistance to radiotherapy. A natural BH3-mimetic, small molecule inhibitor of Bcl-2, (−)-gossypol, shows promise in ongoing Phase II clinical trials for human prostate cancer. We have recently shown that (−)-gossypol preferentially induces autophagy in CRPC cells that have high levels of Bcl-2 and are resistant to apoptosis, both in vitro and in vivo, but not in androgen-dependent cells with low Bcl-2 and sensitive to apoptosis. Our results demonstrate for the first time that (−)-gossypol can interrupt the interaction between Beclin1 and Bcl-2/Bcl-xL at the endoplasmic reticulum, thus releasing the BH3-only pro-autophagic protein Beclin1, which in turn triggers the autophagic cascade. (−)-Gossypol-induced autophagy is Beclin1- and Atg5-dependent, together with Bcl-2 downregulation and Beclin1 upregulation. (−)-Gossypol increased autophagic cell death induced by X-ray radiation in the CRPC cells. Orally administered (−)-gossypol achieved a much greater efficacy with long-term tumor regression when used in combination with ionizing radiation. We have also explored a series of gossypol derivatives and identified two novel BH3-mimetic lead compounds that are more potent than the parental compound in inducing autophagic cell death in CRPC. Taken together, (−)-gossypol significantly enhances the anti-tumor activity of radiotherapy in vitro and in vivo, and represents a promising new regime for treatment of castration-resistant human prostate cancer with overexpression of Bcl-2. Our data provide new insights into the mode of cell death induced by Bcl-2 inhibitors, which would facilitate the rational design of clinical trials by selecting patients who are most likely to benefit from the Bcl-2-targeted molecular therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5085. doi:10.1158/1538-7445.AM2011-5085
PEPTIC ULCER
Authors: BETTIE M. WEST, ARTHUR O. HECKER
Journal: American Journal of Psychiatry (1952)

A survey of the literature as well as of our case material indicates that peptic ulcer is common among psychotic patients, the incidence in hospital populations of mental and general hospitals being within comparable statistical range or perhaps of higher range in mental hospitals. These studies indicate further that the reputed low incidence is based on increased difficulties of diagnosis in the psychotic patient rather than on actual evidence.
FRI0427 Getting a grip on tight control: Predictors of medication escalation in RA in practice
Authors: J. Hendrikx, W. Kievit, J. Fransen, P. van Riel
Journal: Annals of the Rheumatic Diseases (2013)

Background Trials of tight control strategies have shown additional effectiveness over usual care. Despite this, in daily clinical practice medication is not always escalated according to guidelines. It is hypothesized that, additional to attained disease activity level, other clinical factors or patient related factors might explain divergence from tight control. Objectives To investigate factors predicting escalation of medication in rheumatoid arthritis (RA) patients. Methods All RA patients with regular monitoring visits to the Nijmegen outpatient clinic received standard clinical assessment including DAS28 assessment and registration of medication changes. In addition, patients were asked 4 questions regarding: perceived health state transition, satisfaction with their current health state, willingness to change therapy and expected health state transition in the near future. To investigate explanatory factors, three models predicting escalation of medication were compared by means of ROC analyses. Predictors for the respective models were: model 1 (reflecting tight control) DAS28>3.2 (yes/no), model 2 gender, age, rheumatoid factor, disease duration, DAS28 response since last visit + attained DAS28 level, model 3 predictors in model 2 + the above mentioned patient perception parameters. Escalation of medication was defined as an increase in frequency and/or dose of medication, or starting a new drug, between the current and next visit. Results In total 337 RA patients; 65.9% female, 71.5% rheumatoid factor positive were included in the analysis. Mean (SD) DAS28 at visit, age and disease duration in years were: 3.11 (1.24), 59.2 (13.17), 11.2 (9.03), respectively. In total 146 (43.3%) patients had a DAS28>3.2, of whom 79 (54.1%) were satisfied with their health status if this would not change until the next visit and a majority of 96 (65.8%) did not want to change their medication. [Figure 1][1] shows sub specifications of patients according to satisfaction an willingness to change medication. Figure 2 shows clear improvement in the predictive capacity of the models by adding additional clinical and patient related factors. ![Figure][2]</img> Conclusions Including a broader range of clinical and patient related parameters clearly improves the prediction of escalation of care. These results reflect that the decision process to escalate medication in daily clinical practice is more complex than is suggested by tight control guidelines. Interventions aimed at increasing tight control should address additional clinical and patient related factors rather than attained disease activity level alone. Disclosure of Interest None Declared [1]: #F1 [2]: pending:yes
Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset Diabetes
Authors: C. E. Mogensen
Journal: New England Journal of Medicine (1984)

We studied whether microalbuminuria (30 to 140 μg of albumin per milliliter) would predict the later development of increased proteinuria and early mortality in Type II diabetics. During 1973, morning urine specimens of diabetic clinic patients 50 to 75 years of age whose disease had been diagosed after the age of 45 were examined for albumin level by radioimmunoassay. Seventy-six patients with albumin concentrations of 30 to 140 μg per milliliter were identified for long-term follow-up. They were compared with normal controls, diabetic patients with lower albumin concentrations (75 patients with concentrations <15 μg per milliliter and 53 with concentrations of 16 to 29 μg per milliliter), and 28 diabetic patients with higher concentrations (>140). Age, duration of diabetes, treatment method, fasting blood glucose level, blood pressure, height, and weight were determined for the four diabetic groups. After nine years the group with albumin concentrations of 30 to 140 μg per milliliter was more likely to have clinically detectablle 5oteinuria (>400 μg per milliliter) than were the groups with lower concentrations. Mortality was 148 per cent higher in this group than in normal controls — comparable to the increase (116 per cent) in the group with heavy proteinuria (albumin levels >140 μg per milliliter). In addition, mortality was increased 76 per cent in the group with albumin levels of 16 to 29 μg per milliliter and 37 per cent in the group with levels below 15. We conclude that microalbuminuria in patients with Type II diabetes is predictive of clinical proteinuria and increased mortality. (N Engl J Med 1984; 310:356–60.)
The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice
Authors: Zubin Zhang, Jiefei Tong, Xiaowen Tang, Jiaxiang Juan, Biyin Cao, Rose Hurren, Guodong Chen, Paul Taylor, Xin Xu, Chang-xin Shi, Juan Du, Jian Hou, Guanghui Wang, Depei Wu, A. Keith Stewart, Aaron D. Schimmer, Michael F. Moran, Xinliang Mao
Journal: Blood (2016)
Case 71-1962
Authors: Richard A. Field, Benjamin Castleman
Journal: New England Journal of Medicine (1962)

Presentation of Case First admission. A fifty-nine-year-old carpenter entered the hospital for treatment of a gastric ulcer.A duodenal ulcer was diagnosed seventeen years previously. He had ulcer symptoms intermittently, with the occasional passage of tarry stools, for several years and was treated with antacids and sedation. Six months before admission he entered another hospital because of abdominal pain, and the diagnosis of gastric ulcer was made. Subsequently, he was referred to this hospital for an operation.Hypertension was known to have been present for two years; sporadic treatment with various drugs had no effect. Forty years previously the . . .
Incidental Detection of Skeletal Uptake on Sestamibi Cardiac Images in a Patient With Previously Undiagnosed Multiple Myeloma
Authors: CHRISTINE FISHER, AMY VEHEC, BASHAR KASHLAN, GERALD LONGA, LOWELL HOUPT, KRISTI HOWE, LISA STARK, DENNIS CAVANAUGH
Journal: Clinical Nuclear Medicine (2000)

An 81-year-old woman had a history of congestive heart failure with shortness of breath, chest pain, and headaches. A dipyridamole-augmented Tc-99m sestamibi gated SPECT myocardial perfusion scan revealed increased uptake in the axial and appendicular skeleton that increased over time. Subsequent bone marrow biopsy revealed multiple myeloma.
P242 METFORMIN DECREASES THE TLR4 EXPRESSION ON PERIPHERAL BLOOD MONOCYTES OF PATIENTS WITH NAFLD
Authors: A. Zwolak, J. Daniluk, O. Slabczynska, J. Semeniuk, M. Kandefer-Szerszen, A. Szuster-Ciesielska
Journal: Journal of Hepatology (2014)
Transduodenal Sphincterotomy for Chronic Relapsing Pancreatitis
Authors: James W. Major, Edward J. Ottenheimer
Journal: New England Journal of Medicine (1953)

IT is now generally accepted that there are two types of acute pancreatitis: acute pancreatic edema, and acute pancreatic necrosis. Repeated attacks of acute pancreatitis are classified as chronic relapsing pancreatitis that may progress, in rare cases, to pancreatic cysts, fibrosis, lithiasis or calcification. It is possible that all these conditions represent different stages of the same pathologic process.The purpose of this paper is to present observations based on 23 cases of relapsing pancreatitis.Acute pancreatic necrosis is relatively unusual. Acute pancreatic edema, on the contrary, is a common disease. Since Elman,1 in 1935, called attention to it as . . .
RH-01 * THE SIGNIFICANCE OF ACUTE INPATIENT REHABILITATION FOR GLIOMA PATIENTS: IMPROVING THE PHYSICAL FUNCTION, QUALITY OF LIFE AND SURVIVAL
Authors: D. Beverly Fu, D. A. Bota
Journal: Neuro-Oncology (2014)

OBJECTIVE: To assess the effects of inpatient acute rehabilitation on overall function, quality of life and overall survival for glioma patients. DESIGN: A retrospective study of glioma patients treated at UCI Neuro-Oncology Program. PARTICIPANTS: We have identified 12 patients with glioma diagnosis who underwent inpatient acute rehabilitation program using our IRB approved neuro-oncology database. OUTCOME ASSESSMENT TOOLS: Functional status based upon Karnofsky performance scale (KPS), quality of life as assessed by Functional Assessment of Cancer Therapy Brain (FACT-Br) and overall survival. RESULTS: We identified on our study 3 patients with glioblastoma, 7 patients with anaplastic gliomas, and 2 patients with low grade gliomas. All of them had radiation and chemotherapy, except 2 patients with low grade gliomas who had radiation treatment only. The age range is from 26 to 77 and the mean age is 49-year-old. All the patients who underwent the acute inpatient rehabilitation program at our institution, not only improved their KPS scale significantly, but also enhanced their social and emotional well-being. The median KPS improvement is 30 points from a 3-6 weeks stay. Functional Assessment of Cancer Therapy Brain (FACT-Br) is obtained from 4 patients at this time (further information will be presented at SNO conference). The mean FACT-Br TOI is 60.8, and the total FACT0Br Score is 119.6. Survival data are still collected. CONCLUSIONS: The patients who underwent acute inpatient rehabilitation program, showed significant improvements in their functional status and quality of life. The observation from this pilot study warrants further research and demonstrates the acute inpatient rehabilitation may be beneficial to glioma patients with good physical functions and tolerance for 3 hours a day of physical, occupation and speech therapies.
Successful ERCP in a patient with situs inversus
Authors: Şahin Çoban, Ilhami Yüksel, Metin Küçükazman, Ömer Başar
Journal: Endoscopy (2014)

Situs inversus viscerum is a rare condition in which the organs are transposed to the opposite side [1]. Endoscopic procedures can be difficult in patients with situs inversus because of the left–right reversal of the visceral organs. We present a patient with choledocholithiasis who had situs inversus. Endoscopic retrograde cholangiopancreatography (ERCP) was performed with minor modification of maneuvers with the patient lying in the usual left lateral decubitus position.
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Authors: Renee E. Poupon, Raoul Poupon, Beverley Balkau
Journal: New England Journal of Medicine (1994)

Ursodiol (ursodeoxycholic acid) therapy leads to major improvements in patients with primary biliary cirrhosis. The benefit of long-term treatment is uncertain.We randomly assigned 145 patients with biopsy-proved primary biliary cirrhosis to receive ursodiol (13 to 15 mg per kilogram of body weight per day) (72 patients) or placebo (73 patients). After two years of follow-up, because of the benefit from ursodiol, all patients completing the study received ursodiol in an open trial and were monitored for two more years. The end points in the assessment of efficacy were as follows: progression of disease, as defined by the presence of hyperbilirubinemia, variceal bleeding, ascites, or encephalopathy; liver transplantation or a referral for that procedure; and liver transplantation (or a referral) or death.Disease progressed significantly less frequently in the ursodiol group than in the placebo group (P < 0.002; relative risk, 0.28; 95 percent confidence interval, 0.12 to 0.63). The probability of liver transplantation or a referral for that procedure and the probability of transplantation or death were significantly lower in the group assigned to ursodiol than in the group assigned to placebo (for transplantation alone, P = 0.003; relative risk, 0.21; 95 percent confidence interval, 0.07 to 0.66; for transplantation or death, P = 0.005; relative risk, 0.32; 95 percent confidence interval, 0.14 to 0.74). High bilirubin levels and, to a lesser extent, signs of cirrhosis at entry into the trial were predictive of disease progression, liver transplantation or a referral, and transplantation or death.Long-term ursodiol therapy slows the progression of primary biliary cirrhosis and reduces the need for liver transplantation.
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
Authors: Lloyd Paul Aiello, Robert L. Avery, Paul G. Arrigg, Bruce A. Keyt, Henry D. Jampel, Sabera T. Shah, Louis R. Pasquale, Hagen Thieme, Mami A. Iwamoto, John E. Park, Hung V. Nguyen, Lloyd M. Aiello, Napoleone Ferrara, George L. King
Journal: New England Journal of Medicine (1994)

Retinal ischemia induces intraocular neovascularization, which often leads to glaucoma, vitreous hemorrhage, and retinal detachment, presumably by stimulating the release of angiogenic molecules. Vascular endothelial growth factor (VEGF) is an endothelial-cell-specific angiogenic factor whose production is increased by hypoxia.